Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the production of Bromidespasm, a sustained-release tablet used to treat myasthenia gravis, marking a significant milestone in its product development [1] Group 1: Product Approval - The sustained-release tablet of Bromidespasm has been granted a drug registration certificate by the National Medical Products Administration [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - Shanghai Pharmaceuticals submitted the registration application for this drug in March 2024, which has been accepted by the regulatory authority [1] Group 2: Financial Investment - The company has invested approximately RMB 16.09 million in research and development for this drug as of the date of the announcement [1]

Policy Developments - The "14th Five-Year Plan" emphasizes accelerating the construction of a Healthy China, implementing a health-first development strategy, and enhancing public health capabilities [2] - The plan aims to improve the healthcare system, promote the integration of traditional Chinese and Western medicine, and support the development of innovative drugs and medical devices [2] Drug and Device Approvals - Shanghai Pharmaceuticals' bromide pyridostigmine sustained-release tablets have received production approval from the National Medical Products Administration, which is expected to enhance market share and competitiveness [3] - The company has invested approximately RMB 16.009 million in the research and development of this drug [3] Financial Reports - Fosun Pharma reported a 26% year-on-year increase in net profit for the first three quarters of 2025, despite a 4.91% decline in revenue [4] - Haisheng Pharmaceutical achieved a 40.89% increase in revenue and a 47.16% increase in net profit for the first three quarters of 2025 [5] Capital Market Activities - New Tian Di has entered a strategic cooperation agreement with Nanjing Zhihe Pharmaceutical to develop GLP-1 long-acting peptide innovative drugs [6][7] - WuXi AppTec signed strategic cooperation memorandums with NEOM and the Saudi Ministry of Health to explore localized new drug R&D and production services [8] Industry Events - The results of the 11th batch of national drug centralized procurement were announced, including 55 drugs aimed at stabilizing clinical needs and ensuring quality [9][10] - The procurement process has raised the qualification thresholds for bidding companies and aims to prevent collusion in pricing [10] Intellectual Property Developments - The Deputy Director of the National Intellectual Property Administration of China met with representatives from the International Pharmaceutical Alliance to discuss patent protection and dispute resolution mechanisms [11] Shareholder Actions - BioVeda, a major shareholder of AoJing Medical, has completed a share reduction plan, selling 1.3555 million shares, which represents 1% of the company's total equity [12]

Group 1 - Shanghai Pharmaceuticals has received approval for the production of Bromperidol Sustained-Release Tablets from the National Medical Products Administration [1][2] - The drug is classified as a Class 3 chemical drug with a specification of 0.18g per tablet and has been registered under the approval number H20255730 [2] - The drug is indicated for the treatment of myasthenia gravis and was originally developed by BAUSCH, first launched in the United States in 1959 [3] Group 2 - As of the announcement date, no other companies in China have listed Bromperidol Sustained-Release Tablets [4] - According to IQVIA data, the procurement amount for Bromperidol Tablets in hospitals in mainland China is approximately RMB 60.29 million for 2024 [5] - The company has invested approximately RMB 16.009 million in research and development for this drug [3] Group 3 - The approval of the drug is expected to enhance the market share and competitiveness of Shanghai Pharmaceuticals, benefiting from national policies that support newly registered generic drugs in medical insurance and procurement [6] - The company aims to leverage this experience for future generic drug applications [6]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of bromperidol sustained-release tablets, indicating a significant advancement in its product portfolio [1] Company Summary - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyu Chinese and Western Medicine Co., Ltd., has obtained the Drug Registration Certificate for bromperidol sustained-release tablets, with the certificate number 2025S03175 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromidespamine sustained-release tablets, which are indicated for the treatment of myasthenia gravis [1] Group 1 - The product, Bromidespamine sustained-release tablets, was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - The registration certificate number for the approved drug is 2025S03175 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromidespasm, a sustained-release tablet used to treat myasthenia gravis, marking a significant milestone for the company in expanding its product portfolio [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has been granted a Drug Registration Certificate for Bromidespasm, with the certificate number 2025S03175 [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - The company submitted the registration application for this drug to the National Medical Products Administration in March 2024, which has been accepted [1] - As of the date of the announcement, the company has invested approximately RMB 16.09 million in research and development for this drug [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromperidol Sustained-Release Tablets, indicating a significant advancement in its product portfolio [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has been granted a drug registration certificate (Certificate No. 2025S03175) for Bromperidol Sustained-Release Tablets, allowing the company to commence production [1]